专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080107733A1 Formulation Obtained From A Powder Mixture Comprising An Inorganic Pigment 审中-公开
标题翻译：由包含无机颜料的粉末混合物获得的制剂
公开(公告)号：US20080107733A1
公开(公告)日：2008-05-08
申请号：US11597799
申请日：2005-05-30
申请人： Katja Fastnacht , Matthias Degenhardt , Gunther Berndl , Jorg Rosenberg , Jorg Breitenbach
发明人： Katja Fastnacht , Matthias Degenhardt , Gunther Berndl , Jorg Rosenberg , Jorg Breitenbach
IPC分类号： A61K9/14
CPC分类号： A61K9/143 , A61K9/146 , A61K9/2095
摘要： A solid dosage form having a matrix with at least one active compound dispersed homogeneously in the matrix, which is obtainable by melting a powder mixture, wherein the powder mixture comprises at least one thermoplastic binder and a combination of highly disperse silica and at least one inorganic pigment, is described. The co-use of the highly disperse silica and the inorganic pigments leads to better flow properties of the powder mixture, has the effect of a faster release of the active compound from the dosage forms obtained, and imparts a visually pleasing appearance to the dosage forms. A process for the preparation of the dosage form is also described.
摘要翻译：一种固体剂型，其具有通过熔融粉末混合物可获得的具有均匀分散在基质中的至少一种活性化合物的基质，其中所述粉末混合物包含至少一种热塑性粘合剂和高分散二氧化硅与至少一种无机物的组合颜料。高度分散的二氧化硅和无机颜料的共同使用导致粉末混合物的更好的流动性质，具有从所获得的剂型中更快释放活性化合物的作用，并赋予剂型视觉上令人满意的外观。还描述了用于制备剂型的方法。

2. 发明申请

US20110008430A1 Solid Pharmaceutical Dosage Form 有权
公开(公告)号：US20110008430A1
公开(公告)日：2011-01-13
申请号：US12880766
申请日：2010-09-13
申请人： Jorg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
发明人： Jorg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
IPC分类号： A61K9/28 , A61K31/513 , A61P31/18
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

3. 发明申请

US20080299203A1 Solid Pharmaceutical Dosage Formulation 审中-公开
标题翻译：固体药物配方
公开(公告)号：US20080299203A1
公开(公告)日：2008-12-04
申请号：US12190252
申请日：2008-08-12
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman L. Alani , Soumojeet Ghosh
IPC分类号： A61K9/00 , A61K31/513 , A61K31/427
CPC分类号： A61K9/1694 , A61K9/1617 , A61K9/1635 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/204 , A61K9/2077 , A61K9/2095 , A61K9/2866 , A61K31/00 , A61K31/426 , A61K31/427 , A61K31/513 , A61K47/32 , A61P31/18 , A61K2300/00
摘要： The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
摘要翻译：本发明提供药物剂型，更特别地，包含HIV蛋白酶抑制剂的药物剂型。

4. 发明申请

US20050084529A1 Solid pharmaceutical dosage form 有权
公开(公告)号：US20050084529A1
公开(公告)日：2005-04-21
申请号：US10925442
申请日：2004-08-25
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K9/16 , A61K9/20 , A61K31/427 , A61K31/513
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

5. 发明申请

US20070249643A1 SOLID PHARMACEUTICAL DOSAGE FORM 审中-公开
标题翻译：固体药物剂型
公开(公告)号：US20070249643A1
公开(公告)日：2007-10-25
申请号：US11773185
申请日：2007-07-03
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K31/426 , A61K31/505 , A61P31/18
CPC分类号： A61K47/32 , A61K9/10 , A61K9/1617 , A61K9/1635 , A61K9/2077 , A61K9/2095 , A61K31/427 , A61K31/513 , A61K47/26 , Y10S514/937
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

6. 发明申请

US20050143404A1 Solid pharmaceutical dosage formulation 有权
标题翻译：固体药物剂型
公开(公告)号：US20050143404A1
公开(公告)日：2005-06-30
申请号：US11064467
申请日：2005-02-23
申请人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman Alani , Soumojeet Ghosh
发明人： Joerg Rosenberg , Ulrich Reinhold , Bernd Liepold , Gunther Berndl , Jorg Breitenbach , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K9/16 , A61K9/20 , A61K31/427 , A61K31/513
CPC分类号： A61K9/1694 , A61K9/1617 , A61K9/1635 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/204 , A61K9/2077 , A61K9/2095 , A61K9/2866 , A61K31/00 , A61K31/426 , A61K31/427 , A61K31/513 , A61K47/32 , A61K2300/00
摘要： The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
摘要翻译：本发明提供药物剂型制剂，更具体地，涉及包含HIV蛋白酶抑制剂的药物剂型。

7. 发明申请

US20050048112A1 Solid pharmaceutical dosage form 审中-公开
标题翻译：固体药物剂型
公开(公告)号：US20050048112A1
公开(公告)日：2005-03-03
申请号：US10650178
申请日：2003-08-28
申请人： Jorg Breitenbach , Laman Alani , Gunther Berndl , Soumojeet Ghosh , Bernd Liepold , Ulrich Reinhold , Joerg Rosenberg
发明人： Jorg Breitenbach , Laman Alani , Gunther Berndl , Soumojeet Ghosh , Bernd Liepold , Ulrich Reinhold , Joerg Rosenberg
IPC分类号： A61K9/14 , A61K9/20 , A61K9/28 , A61K31/425
CPC分类号： A61K31/425 , A61K9/146 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2866
摘要： A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
摘要翻译：公开了提供改善的口服生物利用度的固体药物剂型，用于HIV蛋白酶的抑制剂。特别地，剂型包含至少一种HIV蛋白酶抑制剂和至少一种药学上可接受的水溶性聚合物和至少一种药学上可接受的表面活性剂的固体分散体，所述药学上可接受的水溶性聚合物的Tg至少为约50 优选地，药学上可接受的表面活性剂具有约4至约10的HLB值。

8. 发明申请

US20120046360A1 FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF 审中-公开
标题翻译：包含非洲酸，生理上可接受的盐或其衍生物的配方
公开(公告)号：US20120046360A1
公开(公告)日：2012-02-23
申请号：US13216888
申请日：2011-08-24
申请人： Joerg Rosenberg , Matthias Degenhardt , Jorg Breitenbach , Tom L. Reiland , Kennan C. Marsh
发明人： Joerg Rosenberg , Matthias Degenhardt , Jorg Breitenbach , Tom L. Reiland , Kennan C. Marsh
IPC分类号： A61K31/216 , A61P3/06 , A61K31/192
CPC分类号： A61K31/56 , A61K9/146 , A61K9/1652 , A61K9/2054 , A61K31/192 , A61K31/205 , A61K31/216 , A61K31/495 , A61K31/58
摘要： A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.
摘要翻译：包含i）非诺贝酸，其生理学上可接受的盐或其衍生物和任选的其它活性物质的制剂，ii）包含至少一种肠溶粘合剂和任选地iii）其它生理上可接受的赋形剂的粘合剂组分。非诺贝酸，其生理学上可接受的盐或衍生物优选为这些制剂中分子分散体的形式。同样描述了其制备的有利方法，特别是通过熔融挤出，以及该制剂用于口服非诺贝酸，其生理学上可接受的盐或其衍生物的用途。

9. 发明申请

US20090050262A1 Production of Dosing Molds from Active Substance-Containing Melts 审中-公开
标题翻译：从含活性物质的熔体生产计量模具
公开(公告)号：US20090050262A1
公开(公告)日：2009-02-26
申请号：US11884521
申请日：2006-02-17
申请人： Jorg Rosenberg , Norbert Steiger , Harald Hach , Jorg Breitenbach
发明人： Jorg Rosenberg , Norbert Steiger , Harald Hach , Jorg Breitenbach
IPC分类号： B32B37/10
CPC分类号： A61J3/10 , A61J2200/20 , B30B11/16
摘要： Disclosed is a method for producing dosing molds, according to which two separating films (7) are contacted with each other in a defined area, an active substance-containing melt is introduced between the separating films (7) such that a pocket for receiving a portion of the melt is embodied in at least one of the separating films, and the separating films (7) are separated from each other in order to eject the portion. Preferably, a method is disclosed in which the separating films (7) are contacted with each other in the gap of two molding rolls (2, 3) which rotate in opposite directions and are provided with opposite recesses (4, 5) on the surface thereof, and into which the separating films (7) can be pressed when the active substance-containing melt is introduced so as to form pockets. The separating films (7) make it possible to avoid a direct contact between the melt and the rolls (4,5) and thus prevent the melt from adhering to the roll (2, 3). Elastically deformable separating films (7) support the ejection process as a result of the stress thereof being released after leaving the roll gap (2, 3).
摘要翻译：公开了一种用于生产定量给料模具的方法，根据该方法，两个分离膜（7）在限定的区域中彼此接触，含活性物质的熔体被引入到分离膜（7）之间，使得用于接收熔体的一部分体现在至少一个分离膜中，并且分离膜（7）彼此分离以便喷射该部分。优选地，公开了一种方法，其中分离膜（7）在沿相反方向旋转的两个成型辊（2,3）的间隙中彼此接触并且在表面上设置有相对的凹部（4,5）并且当引入含活性物质的熔体以形成袋时，分离膜（7）可以被压入其中。分离膜（7）使得可以避免熔体与辊（4,5）之间的直接接触，从而防止熔体粘附到辊（2,3）上。弹性变形分离膜（7）由于在离开辊间隙（2,3）之后其应力释放而支持喷射过程。

10. 发明申请

US20090012184A1 Production of Dosage Forms Comprising a Solid Dispersion of a Microcrystalline Agent 审中-公开
标题翻译：生产包含微晶剂固体分散体的剂型
公开(公告)号：US20090012184A1
公开(公告)日：2009-01-08
申请号：US11884164
申请日：2006-02-09
申请人： Jorg Rosenberg , Markus Magerlein , Bernd Liepold , Jorg Breitenbach
发明人： Jorg Rosenberg , Markus Magerlein , Bernd Liepold , Jorg Breitenbach
IPC分类号： A61K47/30
CPC分类号： A61K9/146 , A61K9/145
摘要： A method is described for the production of dosage forms, which comprise a solid dispersion of a microcrystalline active substance, in which a thermoplastic polymer with a glass transition temperature Tg of at least 40° C. is melted and an active substance is dissolved homogeneously in the melt; crystallization of the active substance is initiated in the mass obtained; and the mass is cooled. Crystallization of the active substance can be initiated by adding a nonsolvent, seed crystals of the active substance or a derivatization reagent. In addition, crystallization can be initiated by holding the mass for a sufficient length of time at a temperature that is below the temperature at which the active substance is completely soluble in the mass.
摘要翻译：描述了用于制备剂型的方法，其包含微晶活性物质的固体分散体，其中玻璃化转变温度Tg至少为40℃的热塑性聚合物熔融并将活性物质均匀地溶解在熔化; 活性物质的结晶在得到的团块中开始; 并且质量被冷却。活性物质的结晶可以通过加入非溶剂，活性物质的晶种或衍生试剂来引发。此外，可以通过在低于活性物质完全溶解于物质中的温度的温度下保持质量足够长的时间来引发结晶。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式